Richard Moulson to join Evgen Pharma as CFO

(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday.The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 February 2017, on which date the current CFO John Bradshaw will leave the company to focus on his work with a new healthcare investment vehicle.Moulson will then join the company's board and become CFO on 1 March.He graduated in zoology at Exeter University before qualifying as an accountant at Coopers & Lybrand.Moulson worked in corporate finance at Deutsche Morgan Grenfell for 10 years before working in financial and company secretarial roles at a number of UK biotechnology and technology companies.Since 2012, he has had a portfolio of interests, including recently as CFO of Cogent Breeding and previously as interim CFO at both ReNeuron Group and Enigma Diagnostics.Evgen also announced that David Howat, who holds the non-board position of chief development officer, will leave the company at the end of March.Howat led the preclinical and early-stage clinical development of the company's lead product - SFX-01 - through to the Phase II trials.The Phase II trials will continue to be managed by senior clinical study manager Dave Chadwick, who will assumes the non-board position of head of clinical operations on 1 March."On behalf of the board, I would like to express our sincere thanks to John Bradshaw for his valuable contribution to the development of Evgen Pharma, including his important role in the Company's IPO," said CEO Stephen Franklin."I would like to welcome Richard Moulson to Evgen Pharma," he continued."Richard is an experienced CFO with a track record in life sciences and we all look forward to his input to the company and to the board".Dr Franklin also thanked Howat for being a "tremendous asset" during Evgen's formative years and helping to take its lead product through to the current patient trials."David leaves us to join an earlier-stage company and the board extends its thanks and wishes him every success in his new role."